Skip to content
Clinical Trials – home
FranceBack to France

Clinical trials in Boulogne-Billancourt – page 193

3 430 clinical trials in Boulogne-Billancourt, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Boulogne-Billancourt at a glance
3 430
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

3 430 trials in Boulogne-Billancourt

Open in trial search

Nephrotic syndrome

Not recruiting

Study of Rituximab, Prednisolone and Betamethasone in Adult Patients with First Episode of Minimal Change Nephrotic Syndrome to Prevent Disease Relapse

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Prednisolone
  • Sponsor:Assistance Publique Hopitaux De Paris

Study Comparing Trastuzumab Deruxtecan with Chemotherapy for Patients with HER2-Low, Hormone Receptor Positive Breast Cancer After Endocrine Therapy Progression

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:AstraZeneca AB

Neoplasm

Not recruiting

Study of RLY-4008 for Patients with Cholangiocarcinoma and Other Advanced Solid Tumors

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:RLY-4008
  • Sponsor:Elevar Therapeutics Inc.

Acute myeloid leukaemia+1

Not recruiting

Study of Emavusertib for Patients with Acute Myelogenous Leukemia or Myelodysplastic Syndrome

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Emavusertib
  • Sponsor:Curis Inc.

Study Comparing Ripretinib and Sunitinib for Patients with Advanced Gastrointestinal Stromal Tumors Previously Treated with Imatinib

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ripretinib
  • Sponsor:Deciphera Pharmaceuticals Inc.

Plasma cell myeloma

Not recruiting

Study of Elranatamab for Patients with Multiple Myeloma Resistant to Proteasome Inhibitors, Immunomodulatory Drugs, and Anti-CD38 Antibodies

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Elranatamab
  • Sponsor:Pfizer Inc.

Study Comparing Avelumab, Cetuximab, and Radiotherapy with Standard Treatments for Patients with Advanced Head and Neck Squamous Cell Carcinoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Avelumab
  • Sponsor:Groupe Oncologie Radiotherapie Tete Cou

Fallopian tube cancer+2

Not recruiting

Study of Nemvaleukin Alfa and Pembrolizumab for Patients with Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Nemvaleukin Alfa
  • Sponsor:Mural Oncology Inc.

Plasma cell myeloma

Not recruiting

Study on Elranatamab and Daratumumab for Patients with Relapsed or Refractory Multiple Myeloma After Prior Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Pfizer Inc.

Liposarcoma

Not recruiting

Study Comparing BI 907828 and Doxorubicin for Patients with Advanced Dedifferentiated Liposarcoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Brigimadlin
  • Sponsor:Boehringer Ingelheim Espana S.A.

Study on Preventing Post-Operative Atrial Fibrillation with Botulinum Toxin Injections in Patients Undergoing Cardiac Surgery

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:IncobotulinumtoxinA
  • Sponsor:Assistance Publique Hopitaux De Paris

Endometrial cancer+1

Not recruiting

Study of NP137 with carboplatin, paclitaxel and pembrolizumab combination therapy for patients with advanced endometrial or cervical cancer who had prior chemotherapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Netris Pharma

Other cities in France

The busiest research cities in the country

All 376 cities in France

Clinical research in Boulogne-Billancourt

What the registry says about research in the country

01 Lung Cancer Research

Multiple clinical trials focusing on non-small cell lung cancer (NSCLC) and novel treatment approaches, including immunotherapy combinations and targeted therapies.

  • Advanced stage treatment evaluation
  • Immunotherapy effectiveness
  • Combination therapy assessment

Studies investigating various treatment strategies for both elderly patients and those with specific genetic mutations.

02 Melanoma Studies

Research centered on advanced melanoma treatment, particularly in high-risk stages and post-surgical care.

  • Adjuvant therapy trials
  • Stage III melanoma management
  • Immunotherapy protocols

Focus on improving survival rates through targeted therapeutic approaches and immune system modulation.

03 Kidney and Cardiovascular Research

Investigations into chronic kidney disease (CKD) treatment and cardiac conditions, including innovative therapeutic combinations.

  • Blood pressure management
  • Cardiac function improvement
  • Disease progression prevention

Studies evaluating new treatment approaches for patients with complex cardiovascular conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.